Kyverna Therapeutics, Inc.
KYTXDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Apr 2027
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
How KYTX's past catalysts played out
Standard lymphodepletion regimen
Lupus Nephritis
Standard of Care Treatment
Myasthenia Gravis
KYV-101
Systemic Sclerosis
KYV-101 anti-CD19 CAR-T cell therapy
Lupus Nephritis
Anti-CD20 mAB
Multiple Sclerosis, Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard lymphodepletion regimen | Phase 3 | Lupus Nephritis | - | - |
Standard of Care Treatment | Phase 3 | Myasthenia Gravis | - | - |
KYV-101 | Phase 3 | Systemic Sclerosis | - | - |
KYV-101 anti-CD19 CAR-T cell therapy | Phase 2 | Lupus Nephritis | - | - |
Anti-CD20 mAB | Phase 2 | Multiple Sclerosis, Primary Progressive | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kyverna Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Kyverna Therapeutics, Inc.'s (KYTX) pipeline across Phase 3, Phase 2. Its lead program is Standard lymphodepletion regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kyverna Therapeutics, Inc.'s next FDA catalyst?→
Kyverna Therapeutics, Inc.'s (KYTX) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYTX biotech catalysts?→
Add KYTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kyverna Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.